Key statistics
On Monday, Arrowhead Pharmaceuticals Inc (ARWR:NSQ) closed at 64.33, -16.19% below its 52-week high of 76.76, set on Jan 06, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 61.50 |
|---|---|
| High | 65.19 |
| Low | 61.26 |
| Bid | 63.90 |
| Offer | 66.20 |
| Previous close | 63.27 |
| Average volume | 2.06m |
|---|---|
| Shares outstanding | 140.03m |
| Free float | 134.67m |
| P/E (TTM) | 41.06 |
| Market cap | 8.86bn USD |
| EPS (TTM) | 1.54 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
- Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
- Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
- Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
- Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
- Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
- Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
- Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
More ▼
